Public Citizen Calls for Boxed Warning on Top-Selling Hypertension Drugs

Public Citizen is urging the FDA to require boxed warnings on the labels of many top-selling hypertension drugs, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and Novartis’ aliskiren, to warn against their use in combination. When taken together in any combination, there is an increased risk of side effects such as kidney failure, low blood pressure and elevated potassium levels, the group said in an Oct. 4 petition.
Washington Drug Letter